Received Sep 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | UNK | Y006392 | — |
No additional adverse event reported; Medical assistant called to report that another medical assistant in the facility administered PEDVAX HIB subcutaneously rather than intramuscularly. The caller reports that the documentation states it was administered intramuscularly; however, a pic; Information has been received from Business Partner/CRO on 10-Sep-2025. This spontaneous report was received from a other health professional and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 08-Sep-2025, the patient started therapy with Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (LIQUID PEDVAX HIB), (lot #Y006392, expiration date: 08-Nov-2026) for an unknown indication. On 08-Sep-2025, the vaccine was administered subcutaneously rather than intramuscularly (Intramuscular formulation administered by other route). No additional adverse event was reported.